Obesity and cardiovascular disease: an ESC clinical consensus statement

The global prevalence of obesity has more than doubled over the past four decades, currently affecting more than a billion individuals. Beyond its recognition as a high-risk condition that is causally linked to many chronic illnesses, obesity has been declared a disease per se that results in impaired quality of life and reduced life expectancy. Notably, two-thirds of obesity-related excess mortality is attributable to cardiovascular disease. Despite the increasingly appreciated link between obesity and a broad range of cardiovascular disease manifestations including atherosclerotic disease, heart failure, thromboembolic disease, arrhythmias, and sudden cardiac death, obesity has been underrecognized and sub-optimally addressed compared with other modifiable cardiovascular risk factors. In the view of major repercussions of the obesity epidemic on public health, attention has focused on population-based and personalized approaches to prevent excess weight gain and maintain a healthy body weight from early childhood and throughout adult life, as well as on comprehensive weight loss interventions for persons with established obesity. This clinical consensus statement by the European Society of Cardiology discusses current evidence on the epidemiology and aetiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes. The document aims to raise awareness on obesity as a major risk factor and provide guidance for implementing evidence-based practices for its prevention and optimal management within the context of primary and secondary cardiovascular disease prevention.

Authors

Institutions

Publication Details

Journal
European Journal of Preventive Cardiology
Published
2024-08-30
DOI
https://doi.org/10.1093/eurjpc/zwae279
Citations
90
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
40.30
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Obesity and cardiovascular disease: an ESC clinical consensus statement

Charalambos Antoniades, Nikolaus Marx, Henner Hanssen, Emeline M. Van Craenenbroeck et al.
90 citations
European Journal of Preventive Cardiology
Pharmacology and Obesity Treatment
40.30
article

Obesity and cardiovascular disease: an ESC clinical consensus statement

Charalambos Antoniades, Nikolaus Marx, Henner Hanssen, Emeline M. Van Craenenbroeck, Theresa A. McDonagh, Geltrude Mingrone, Annika Rosengren, Matthias Blüher, Thomas M. Gorter, Eva Prescott, Konstantinos C. Koskinas
article en
90 citations

Abstract

The global prevalence of obesity has more than doubled over the past four decades, currently affecting more than a billion individuals. Beyond its recognition as a high-risk condition that is causally linked to many chronic illnesses, obesity has been declared a disease per se that results in impaired quality of life and reduced life expectancy. Notably, two-thirds of obesity-related excess mortality is attributable to cardiovascular disease. Despite the increasingly appreciated link between obesity and a broad range of cardiovascular disease manifestations including atherosclerotic disease, heart failure, thromboembolic disease, arrhythmias, and sudden cardiac death, obesity has been underrecognized and sub-optimally addressed compared with other modifiable cardiovascular risk factors. In the view of major repercussions of the obesity epidemic on public health, attention has focused on population-based and personalized approaches to prevent excess weight gain and maintain a healthy body weight from early childhood and throughout adult life, as well as on comprehensive weight loss interventions for persons with established obesity. This clinical consensus statement by the European Society of Cardiology discusses current evidence on the epidemiology and aetiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes. The document aims to raise awareness on obesity as a major risk factor and provide guidance for implementing evidence-based practices for its prevention and optimal management within the context of primary and secondary cardiovascular disease prevention.

European Journal of Preventive CardiologyVol. 32(3)
University of Bern (CH), University of Copenhagen (DK), University Medical Center Groningen (NL), University of Antwerp (BE), King's College - North Carolina (US), King's College London (GB), University of Basel (CH), University Hospital of Bern (CH), Sahlgrenska University Hospital (SE), Frederiksberg Hospital (DK), Bispebjerg Hospital (DK), Agostino Gemelli University Polyclinic (IT), Helmholtz Zentrum München (DE), University of Oxford (GB), Antwerp University Hospital (BE), University Hospital Leipzig (DE), King's College Hospital (GB), University of Gothenburg (SE), RWTH Aachen University (DE)
Good health and well-being
Openalex Percentile: Top 0%
Pharmacology and Obesity Treatment
40.30
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.